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Abstract
Glioblastoma multiform (GBM) is a highly malignant brain tumor. Bevacizumab is a recent therapy for stopping tumor
growth and even shrinking tumor through inhibition of vascular development (angiogenesis). This paper presents a non-
invasive approach based on image analysis of multi-parametric magnetic resonance images (MRI) to predict response of
GBM to this treatment. The resulting prediction system has potential to be used by physicians to optimize treatment plans
of the GBM patients. The proposed method applies signal decomposition and histogram analysis methods to extract
statistical features from Gd-enhanced regions of tumor that quantify its microstructural characteristics. MRI studies of 12
patients at multiple time points before and up to four months after treatment are used in this work. Changes in the Gd-
enhancement as well as necrosis and edema after treatment are used to evaluate the response. Leave-one-out cross
validation method is applied to evaluate prediction quality of the models. Predictive models developed in this work have
large regression coefficients (maximum R
2=0.95) indicating their capability to predict response to therapy.
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Introduction
Brain tumors are considered amongst the most refractory
malignancies. Although several therapies have been developed to
improve outcomes in such patients, benefits have been relatively
modest. Glioblastoma (GBM) is the most malignant type of brain
tumor and constitutes about 23% of all primary brain tumors [1].
Multimodal treatment including surgery, radiation, and chemo-
therapy are used but outcomes remain limited [2,3].
As tumors need oxygen and substrates for growth, they express
growth factors stimulating endothelial cell proliferation and
capillary sprouting; or angiogenesis. Vascular Endothelial Growth
Factor (VEGF) which initiates the endothelial proliferation is a
prime mover in this process. Bevacizumab (Avastin; Genentech,
South San Francisco, CA) is a humanized monoclonal antibody
which sequesters the ligands VEGF-A and -B inhibiting angio-
genesis [4,5]. Bevacizumab has received accelerated approval
from the US FDA for the treatment of refractory GBM.
A problem with current therapies is that their impact on a
particular patient may not be known ahead of time, not to mention
the significant costs. As such, after several months of treatment, the
treatment results may not be satisfactory. A predictive model of the
tumor response to treatment is thus very helpful to the physicians
and patients as it allows them to select the most effective option.
Mardor, et al. [6] addressed this problem using two parameters
of diffusion weighted imaging (ADC and RD) in pre-treatment
images and showed that these parameters were correlated with the
response, defined as relative change in the tumor size. Bezabeh,
et al. [7] used several parameters of MR spectroscopy, such as
elevation of choline resonance, to predict the response of head and
neck cancer to radiation therapy. Chen, et al. [8] demonstrated
that positron emission tomography and the fluorothymidine, as an
imaging biomarker, could be used to predict response of malignant
glioma to a combination of bevacizumab and irinotecan therapy.
Moffat, et al. [9] utilized functional diffusion map imaging bio-
marker and concluded that chemotherapy dose was correlated
with this biomarker and the dose itself was also correlated with the
response. Lemaire, et al. [10] examined tumor treatment in rats
and reached the conclusion that there were some relationships
between pre-treatment diffusion weighted parameters (e.g., ADC)
and the tumor size several days after the therapy. Baurle, et al. [11]
investigated the predictability of the response in patients with
breast cancer bone metastasis and showed that the change in the
lesion size can be assessed much earlier via the DCE-MRI
biomarkers. Swanson, et al. [12] developed a model for computing
the rate of change in the glioma cell concentration and for
estimating the patients’ survival, mainly based on two biological
factors (net rates of proliferation and diffusion) [13].
Development of a prediction system requires at least two series of
images acquired from a number of patients to specify some measure
of response. Additionally, using serial images, changes of specific
biological and imaging parameters may be traced and their
relationship with treatment and time may be investigated. Therefore,
many studies have focused on this aspect of medical imaging. There
are several sources of error and variance in these images that should
be carefully considered in their analysis [14,15,16,17,18].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29945The purpose of this work is to establish a relationship between
multi-parametric MRI, including T1-weighted pre-Gd (T1-pre),
T1-weighted post-Gd (T1-post), T2-weighted (T2), and Fluid
attenuated inversion recovery (FLAIR) images acquired pre-
treatment, and the reduction in the Gd-enhanced volume due to
bevacizumab treatment. The differences among the Gd-enhanced
regions of different patients in terms of their homogeneity and
brightness has motivated us to extract their characteristics and
features to stratify responders from non-responders and develop a
predictive model for the level of response. In addition, analysis of
the data acquired from the patients in several consecutive imaging
series (including the pre-treatment session) is performed to see how
the patients’ conditions are affected by the therapy and how the
tumor characteristics are influenced during the treatment time
interval. To the best of our knowledge, this work is the first study
that uses multi-parametric structural MRI to predict the response
to therapy.
Materials and Methods
Ethics Statement
This research has been approved by the Henry Ford Health
System Institutional Review Board. We obtained written informed
consent from all participants in the study.
Twelve patients (9 males, 3 females; age range 36–66, mean 54)
with GBM and Gd-enhanced areas in their T1-post were chosen
for the study. All of the patients had edema encompassing the
tumors and 8 patients had necrosis. Tables 1 and 2 present tumor
locations, treatments delivered, imaging characteristics, age, and
gender of the patients.
Several series of MR images were acquired for the patients,
once before starting the treatment and then with the time intervals
of 1–3 months after the treatment (Henry Ford Health System,
Detroit, MI, USA). These images were acquired using a 3 T GE
system and included multi-parametric images with an image
matrix size of 5126512: T1-weighted with TR/TE/TI=3000/6/
1238 ms, T1-post with TR/TE/TI=3000/6/1238 ms, T2-
weighted with TR/TE=3000/103 ms, and FLAIR with TR/
TE/TI=10000/120/2250 ms. The images had high quality and
were already co-registered, so no noise reduction or registration
step was applied. The patients had different number of image
acquisitions. For example, whereas five patients had four series of
image acquisitions, four patients experienced three series, and
three patients had two series of images. Because of this non-
uniformity, the prediction of the response to therapy was done
based on the second image series. Time intervals between the first
two series of images of the patients range from 41 days to 83 days.
First, all slices in the T1-post images of each patient were
examined to select the ones with Gd-enhanced areas for volume
analysis. Then, the skull was removed in the selected slices
using Eigentool (http://www.radiologyresearch.org/eigentool.
htm). Next, Gram-Schmidt orthogonalization was applied to the
baseline MR images. As explained below, this approach
decomposes the multi-parametric MRI data into white matter
(WM), gray matter (GM), cerebrospinal fluid (CSF), and the
remainder (orthogonal) composite images [19]. Imaging features
are later extracted from these composite images. The application
of Gram-Schmidt orthogonalization makes the analysis indepen-
dent of the intra- and inter-patient variations in intensity and
contrast of the MR images, thus resulting in features robust to such
variations.
Initially, some samples from the pixels of each region to be
segmented (i.e., WM, GM, and CSF) are manually chosen. These
pixels are considered as the desired tissue pattern and the pixels
from the other regions are regarded as undesired tissue patterns.
Each composite image is constructed using a weighting vector that
projects the original multi-dimensional vectors defined using the
original MR images to a specific subspace:
CIjk~
X 4
i~1
WiVjki~W:
 !
Vjk
 !
where CIjk is the intensity of the (j, k)
th pixel in the composite
image, W
 !
is the weighting vector, and vjk  ! is the intensity vector
of the (j, k)
th pixel in the original MR images. To find the
weighting vector of each composite image, its SNR is maximized
while the inner products of the weighting vector with the other
Table 1. Summary of patients, locations of tumors, and treatments delivered at different dates.
Patient ID Tumor Location Date of Diagnosis
First Progression
Date Recorded
Last Progression
Date Recorded Treatments Delivered at Different Dates
1670 L Frontal 8/29/2006 10/3/2006 9/27/2007 EBRT+TMZ, TMZ, Iri+Bev, Bev+Tar
178 R Frontal 1/25/2002 9/9/2002 12/17/2008 EBRT, CCNU, Pro, Iri, TMZ, Iri, Bev, EM1421
1125 Multiple 3/17/2006 9/28/2006 3/13/2008 EBRT+TMZ+Tal, TMZ, Bev
1847 L Temporal 6/19/2006 10/5/2006 5/23/2007 EBRT+TMZ, TMZ, Iri+Bev
1197 L Frontal 4/1/1994 2/1/1999 11/9/2010 EBRT, BCNU, PCV, SRS, TMZ, Iri, Iri+Bev, TMZ+Bev
1170 R Parietal 8/28/2003 1/21/2005 3/31/2009 EBRT+TMZ, TMZ, SRS, TMZ, CPT11+Bev
972 R Frontal 12/23/2005 7/1/2006 5/5/2008 EBRT+TMZ, TMZ, Iri+Bev, TMZ
969 L Occipital 12/19/2005 8/10/2006 10/5/2010 EBRT+TMZ, TMZ, Iri+Bev, AT-101, TMZ
102 L Temporal 8/7/2000 1/20/2003 7/5/2006 EBRT, TMZ, Bev, Bev+Iri, Bev+Car
852 L Temporal 10/27/2005 5/18/2006 1/23/2007 EBRT+TMZ, TMZ, Iri, Bev
1876 R Temporal 1/22/2005 4/2/2007 - EBRT+TMZ, TMZ, Iri+Bev
1589 R Temporal 8/14/2006 4/24/2007 11/29/2007 EBRT+TMZ+Cil, TMZ, MLN-518, TMZ+Bev
The following abbreviations are used: External Beam Radiation Therapy (EBRT), Temozolomide (TMZ), Bevacizumab (Bev), Irinotecan (Iri), Caroplatin (Car), Procarbazine
(Pro), Talamanel (Tal), Ciligentide (Cil), Tarceva (Tar), Lomustine (CCNU), Carmustine (BCNU), Stereotactic Radio-Surgery (SRS), Procarbazine, CCNU and Vincristine (PCV),
targeted chemotherapy agents (MLN-518, AT-101), irinotecan aka Camptosar (CPT11), targeted chemotherapy agent (EM1421).
doi:10.1371/journal.pone.0029945.t001
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weighting vector is:
w !~ t !
d{ t !
d
p
where t !
d is the desired tissue vector and t !
d
p
is the projection of
t !
d onto the undesired tissue vectors (subspace). The latter can be
calculated using the Gram-Schmidt orthogonalization procedure
[21].
The above step was also implemented and applied in Eigentool.
In this approach, different regions of the affected area are
distributed into different composite images. For example, the Gd-
enhanced area of the tumor appears in the WM, CSF, and
orthogonal images but not in the GM image. Also, the edema is
mostly projected onto the GM image. Note that the projection is
based on MR image intensity, not physical location of the tissues.
Edema is more similar to GM than to WM in the images. Figures 1
and 2 show original and composite images for sample responder
and non-responder patients (as defined later), respectively. Note
Table 2. Summary of the imaging characteristics of the patients along with age and gender information.
Patient ID Gd-enhancement Necrosis Age Gender
1670 Irregular Inside Gd-enhancement 62 M
178 Irregular No 36 M
1125 Round Inside Gd-enhancement 66 F
1847 Irregular Inside Gd-enhancement 62 M
1197 Small but scattered Very sparse 49 M
1170 one round, one irregular Two regions, one inside Gd 47 M
972 Round, inside gray matter No 56 F
969 Irregular Not adjacent with Gd-enhancement 60 M
102 Irregular, scattered No 52 M
852 Round and Irregular Inside Gd-enhancement 57 M
1876 Two round and irregular foci Two regions, both inside Gd 41 F
1589 Round and irregular No 55 M
All patients had edema.
doi:10.1371/journal.pone.0029945.t002
Figure 1. An FOV from multi-parametric MRI and the resulting composite images of a responder. (Patient ID: 1125), 1st row: MR images
before the treatment (T2, FLAIR, T1-pre and T1-post, respectively from left to right). 2nd row: Composite images (WM, GM, CSF and Orthogonal,
respectively from left to right). 3rd row: MR images acquired 41 days after the treatment. Red ROIs show borders of Gd-enhanced region on different
images.
doi:10.1371/journal.pone.0029945.g001
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decreased. Also, note that the Gd-enhanced region is clearly
visualized (segmented) in the orthogonal images.
To define the Gd-enhanced area, the T1-post image was
divided by the T1-weighted image pixel by pixel and the result
theresholded. This method requires that the two images have
similar brightness. To this end, a normalization step was applied to
the images by selecting an ROI in the unaffected WM on the T1-
pre image and its corresponding region in the T1-post image.
Then, the average intensities of the pixels in this region of the two
images were calculated and the relative gain of the two images was
obtained by dividing their average intensities. The gain was used
for the normalization of the images.
The process of ROI definition was performed for the edema
and necrosis as well. For this aim, a simple thresholding was
applied to the FLAIR and T1-post images to extract edema and
necrosis, respectively. To treat all of the ROIs equally, an identical
threshold should be used for all of the images from the same
modality. Therefore, the adverse effect of the intensity gain in
some images (especially in FLAIR images) was eliminated by
normalization of the intensities. For example, to extract the ROI
of edema, the edema in a sample FLAIR slice was first segmented
manually. Then, the average intensity of this region was computed
and divided by the average intensity of an arbitrary ROI in the
Figure 2. An FOV from multi-parametric MRI and the resulting composite images of a non-responder. (Patient ID: 178), 1st row: MR
images before the treatment (T2-weighted, FLAIR, T1-weighted and T1-post, respectively from left to right). 2nd row: Composite images (WM, GM,
CSF and Orthogonal feature, respectively from left to right). 3rd row: MR images, acquired 50 days after the treatment. Red ROIs show borders of Gd-
enhanced region on different images.
doi:10.1371/journal.pone.0029945.g002
Figure 3. Interpreting the properties of skewness and kurtosis
in histograms.
doi:10.1371/journal.pone.0029945.g003
Figure 4. Averages of normalized volumes of Gd-enhance-
ment, edema, and necrosis for all patients after treatment.
doi:10.1371/journal.pone.0029945.g004
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value in all other FLAIR slices and define volumetric ROI of the
edema. Although this method may not be very accurate, it is
sufficient for our study because histogram features are utilized that
consider the pixels in the ROI as an aggregate and thus a few pixel
outliers do not affect the resulting features.
Using the ROI of the Gd-enhancement and the thickness of
each slice, the volume of the Gd-enhanced area was computed.
This process was repeated for all of the image series. Then, the
relative change in the volume of the Gd-enhancement between the
baseline and second image series was recorded as a measure of
response. This is due to the limitation that only two images series
were acquired for some of the patients.
Next, a central slice of each volume was chosen for statistical
feature extraction (tissue characterization). It should be noted that
the tissue characteristics can be reliably measured in the areas
Table 3. Tumor volumes and treatment effects on the tumors and time lengths between acquisitions as well as survival length.
Patient ID
Tumor volume in CC
(Gd-enhancement+Edema+Necrosis)
Relative change in
the volume of Gd-
enhancement (%)
Edema
relative
change (%)
Necrosis
relative
change (%)
Time between
the two image
acquisitions (days)
Survival after
treatment
(days)
1670 89.21 54 47 49 58 225
178
* 129.90 32 32 - 50 259
1125 56.16 69 51 66 41 336
1847 176.49 67 40 50 41 210
1197
* 131.67 39 10 235 4 2 7 5
1170 53.37 72 40 46 43 337
972 33.05 83 83 - 42 343
969
* 18.73 23 220 246 52 390
102
* 100.48 78 0 - 75 396
852 120.64 67 51 5 40 209
1876 252.85 75 85 46 52 863
1589 70.83 55 93 - 83 528
Tumor volumes before bevacizumab treatment as well as relative changes in the Gd-enhancement, edema, and necrosis, between baseline MRI and the one acquired
about 2–3 months after the treatment, calculated by (V12V2)/V1, length of time between two image acquisitions, and survival times of the patients.
(*:tumors without necrosis or those with minimal adjacency of Gd-enhanced and necrotic areas).
doi:10.1371/journal.pone.0029945.t003
Figure 5. Comparison of image histogram in different tissues in responders and non-responders. Average histograms of GM image
(left), WM image (middle), and CSF image (right) for non-responders (top row) and responders (bottom row).
doi:10.1371/journal.pone.0029945.g005
Predicting GBM Response to Bevacizumab Treatment
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29945without considerable partial volume effects. The central slice has
the minimum amount of partial volume and thus can yield the
most accurate tissue features [20]. In this step, ROI of the Gd-
enhanced area was overlaid onto the composite images (WM, GM,
and CSF) and their histograms were calculated. Then, a
normalization step was applied to them to compensate for the
effect of the ROI size. Four histogram features (Mean, standard
deviation, skewness, and kurtosis) were extracted. Mean and
standard deviation, represent average and dispersion of the
histogram, respectively. Skewness is a measure of the histogram
asymmetry and kurtosis reflects sharpness of the histogram peak
[22]. The properties of the last two parameters are illustrated in
Figure 3. Altogether, 12 features were extracted from the three
composite images. Note that the features are extracted from
baseline MR images, whereas the response is measured by
comparing the baseline and second series of MR images.
We established one-dimensional and multi-dimensional rela-
tionships between the proposed features and the extent of response
in patients. To this end, single and multiple-regression analyses
were done on the results. Prediction equations and the
corresponding regression coefficients were derived from these
analyses. To control the false discovery rate, we adopted the
multiple testing algorithm proposed in [23]. In addition, leave-
one-out cross validation was performed on the data to evaluate the
predicted results based on the actual responses of the patients.
Also, changes in the volumes of edema and necrosis were
evaluated to investigate if they had any relationship with the
response of the brain tumor to treatment.
Besides these statistical features, we also analyzed the shape and
size of necrotic areas of the tumors to see if there were any
dependencies between these parameters and the amount of
response to the therapy in the patients. This region was selected
Table 4. The three features most significantly correlated with the response to therapy.
Feature Regression coefficient (R
2) Correlation coefficient with the response (R) p-value
GM-std 0.68 20.83 p,0.0009
WM-std 0.51 20.72 p,0.009
CSF-std 0.38 20.62 p,0.03
doi:10.1371/journal.pone.0029945.t004
Figure 6. Response versus features extracted from the GM composite image.
doi:10.1371/journal.pone.0029945.g006
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treatment (It will be discussed in conclusion).
Results
The volumes of Gd-enhancement, edema, and necrosis were
estimated for all patients at different acquisition times. The volume
of each region was normalized to its baseline volume. Then, an
overall curve of size versus time was obtained for each region by
averaging the values estimated for all patients. Figure 4 illustrates
the average curves for the Gd-enhanced area, edema, and
necrosis, up to 83 days after the treatment. On average, Gd-
enhanced and Necrosis regions decreased in size whereas edema
initially decreased but then increased.
All patients experienced a decrease in the Gd-enhanced region.
Table 3 reports the relative volume change of the Gd-enhanced
area for the second series of images computed as (V12V2)/V1,
along with the time between the first two image acquisitions and
the survival days. This relative change was chosen as a measure of
response because it is a normalized version of what is considered a
clinical measure of response.
Next, the histograms of the Gd-enhanced region of each patient
in the composite images were generated. Figure 5 demonstrates
the average histograms of the resultant composite images for the
responders (response .50%) and non-responders (response
,50%). A significant difference is observed in the shapes of the
histograms between the responders and the non-responders, in
particular for the GM and WM composite images. This suggests
that it might be possible to predict the response to therapy using
the histogram statistics. Therefore, the four features described in
the previous section were extracted from the histograms of WM,
GM, and CSF composite images resulting in 12 features. The
central slice of the tumor was selected to minimize the partial
volume averaging effects.
Linear single-regression analysis was performed to develop a
model for estimation of the response to therapy using individual
features. The features with highest correlation with the response to
therapy are presented in Table 4. As we are testing 12 features
individually to evaluate how well they are correlated with the
response to therapy by reporting their p-values, we need to make
corrections in this multiple testing experiment to avoid false
discovery. To control the false discovery rate, we adopted the
algorithm proposed in [23]. Considering 12 hypotheses corre-
sponding to the 12 features, we tested all the p-values [24] and
found GM-std and WM-std significantly correlated to the response
to therapy. The standard-deviation of the GM composite image
was, in particular, the best predictor of the response with the
highest regression coefficient (p,0.0009, R=20.83). Figures 6, 7
and 8 show the plots of response versus individual features
extracted from the GM, WM and CSF composite images,
respectively. Regression lines and prediction equations are
presented for all cases.
To improve the prediction, linear multiple-regression was also
applied to the data which improved the regression coefficient
(Table 5). A maximum regression coefficient of 0.95 (Significance
F=0.0008, R
2=0.95) was achieved which is superior to the single-
regression with the maximum regression coefficient of 0.68. The
candidate variables for this analysis were chosen from the ones
Figure 7. Response versus features extracted from the WM composite image.
doi:10.1371/journal.pone.0029945.g007
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them could estimate the response quite well. Actually multiple
regression analysis was expected to give us a significantly higher
regression coefficient because nearly most of the extracted features
were almost uncorrelated (Table 6). It should be noted that in the
multiple-regression, the measure of ‘‘Significance F ’’ is used to
determine the statistical significance of the results [25].
Survival length was considered as another measure of the
response to therapy [26]. The median progression free survival of
the patients was 336 days. However, no significant correlation
between this measure and the extracted features was found
(Significance F,0.19).
By comparing Tables 2 and 3, it can be seen among the patients
who had necrosis (8 patients), in 6 of them, the response was
higher than 50%. This motivated us to look for relationships
between size or shape of necrotic area and response to therapy.
Although no dependency was found between the two, we observed
that the tumors in which the necrotic area was inside the Gd-
enhanced area and the tumors that had the largest interface
between these two areas had highest levels of response (Tables 2
and 3).
Next, we analyzed the correlation between the relative changes
in the Gd-enhanced area (response), edema, and necrosis (Table 3).
There was a high correlation (p,0.006, R=0.83) between the Gd-
enhanced area relative change (response) and the necrotic area
relative change in the patients with necrosis. There was no
significant correlation (p,0.23, R=0.35) between the relative
changes in edema and the response to therapy. However, a high
and significant correlation coefficient (p,0.0007, R=0.91) be-
tween these two markers was achieved for the tumors with
necrosis. Besides, we found a strong correlation between relative
changes in edema and necrosis (p,0.02, R=0.8).
Finally, we performed a leave-one-out cross validation analysis to
verify the goodness of fit for the linear model. To this end, using
relative change in the size of the Gd-enhanced region as the
measure of response and the five features in the last row of Table 5,
Figure 8. Response versus features extracted from the CSF composite image.
doi:10.1371/journal.pone.0029945.g008
Table 5. Multiple regression results for the prediction of the response to therapy using imaging features.
Features Regression coefficient (R
2) Significance F
stdGM+stdWM 0.73 0.003
stdGM+skewGM+kurtGM 0.87 0.0007
stdGM+skewGM+kurtGM+stdWM+meanWM 0.95 0.0008
doi:10.1371/journal.pone.0029945.t005
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eliminating one patient at a time. Then, using the generated linear
model,weestimatedtheresponsefortheremainingpatient.Figure9
compares the estimated and actual values for the 12 patients.
Discussion
In this study, patients with GBM and Gd-enhanced areas
were studied to establish a correlation between the response to
bevacizumab treatment and features extracted from the structural
MR images. Since the Gd-enhanced area of the tumor reflects the
most active region of the tumor, the relative change in the volume
of this region was considered as a measure of response. The
enhancementofthisregioninthe post-contrastimagesismainlydue
to the leaky capillaries and vessels in the tumor area that allow
passage of the contrast agent into the inter-cellular space as a result
of their damaged blood brain barrier. The angiogenesis process that
facilitates tumor growth makes new vessels weak and highly
permeable [27]. Anti-angiogenic therapies control the development
of new capillaries and as a result control and even reduce the size of
Gd-enhanced area [27]. Therefore, the change in the volume of the
Gd-enhanced region reflects the impact of anti-angiogenic treat-
ment on the patients and was evaluated in this work.
Gram-Schmidt orthogonalization analysis was used as it
generates more robust features compared with the conventional
methods of MRI feature extraction [28]. In this analysis, the gray
levels of the desired tissue in the composite images are always
distributed around unity and thus, regardless of the intensities of
the original images, normalization is not needed.
To develop predictive models of response, single-regression was
used to test the correlation between the extracted features and the
response to therapy within 1–3 months post-treatment. We used
linear regression model which is a model with the minimum
number of parameters and potentially highest generalization.
Although non-linear models are able to better fit the data, they
need a larger number of samples to estimate the model parameters
and may have relatively poor generalization. The resultant
regression coefficients showed that the linear model was
appropriate for our goal.
Relative change in the Gd-enhanced volume was chosen as a
measure of response because it provides a more accurate tumor
assessment compared with the other methods such as 1D or 2D or
even 3D measurements where volume assessment is based on the
major diagonal diameters of the tumor [29,30].
The standard deviation of the GM histogram was found to be the
most significantfeature forthepredictionof the responseto therapy.
This was to some extent predictable because the standard deviation
of the histogram of a specific ROI represents the heterogeneity of
the corresponding cancerous tissue and the more a tumor is
heterogeneous, the more dangerous and fatal it is which means
there is less chance for being able to treat the tumor [31,32].
Multiple-regression was also performed to attain a more
accurate prediction relative to the single-regression analysis. This
is due to the fact that each of the variables used for the regression
was predictive of the response and most of them were almost
uncorrelated (Table 6). On the other hand, the GM-std and WM-
std were found highly correlated (Table 6). That is why combining
WM-std and GM-std increased the regression coefficient by only
0.02. This is consistent with a finding in [6] where two features
(ADC and a diffusion index named RD) were used for prediction.
Although both features predicted the response with a good
correlation (R=0.76 and 0.77, respectively), they were highly
correlated (R=0.95) and thus multiple-regression analysis did not
improve the prediction accuracy.
We found that the tumors with necrosis adjacent to the Gd-
enhanced areas were more likely to respond to treatment relative
to the other tumors. This may be due to the fact that the cells
surrounding the necrotic areas are influenced by hypoxia which
makes them express the highest amount of VEGF among the
tumor cells [33,34]. This leads us to believe that angiogenesis may
be the main mechanism behind the growth of these tumors.
Table 6. Correlation coefficients between the features used
in the multiple regression analysis.
Features Correlation coefficient
stdGM vs. skewGM 0.001
stdGM vs. kurtGM 0.15
stdWM vs. meanWM 0.51
stdGM vs. stdWM 0.95
doi:10.1371/journal.pone.0029945.t006
Figure 9. Comparison of the actual responses and estimates responses using Leave-One-Out method. Responses estimated using leave-
one-out and the five features in the last row of Table 5 (red columns) compared to actual results (blue columns). The relative change in the size of the
Gd-enhanced region was used as the measure of response. The horizontal axis shows the patient that has been eliminated in leave-one-out analysis.
doi:10.1371/journal.pone.0029945.g009
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the best treatment in such cases. In addition, we noted that
bevacizumab has favorably influenced the tumors without necrosis
but this influence is not as strong. This result is in concordance
with the findings of [35]. Figure 10 displays GBM tumors in 3
patients where in (a), the Gd-enhanced area is not fully-adjacent to
necrosis, in (b) there is a maximum of adjacency between these two
regions and in (c) the tumor lacks necrosis.
It seems that bevacizumab has not had a positive impact on the
edema in the long term (Figure 4). One reason may be the fact that
angiogenesis is not the only effective factor for the edema growth
[36,37]. However, it can be seen in Table 3 that the four lowest
levels of decrease in the edema size between the first two image
acquisitions happened for the tumors without necrosis or those with
minimal adjacency of Gd-enhanced and necrotic areas (starred in
the table). These results suggest that there is unlikely that
angiogenesis would be the main factor for tumor infiltration and
development in these cases. This may be one potential explanation
to why an anti-angiogenic therapy has not worked well for these
cases. It should be also noted that these relative changes are just for
second series ofthe imagesand many of the patients had an increase
in their edema size after a while as it can be seen in Figure 4.
Analysis of the necrotic area was also performed in this study.
Figure 4 reveals that the average normalized size of this region in
patients with necrosis, at the end of the treatment trial, has
considerably decreased. This is in contradiction with a statement
in [38] suggesting that the change in the necrotic area would only
be possible through surgery.
Leave-one-out cross validation analysis was performed to
compare predicted and actual responses of the patients. For some
patients, the predicted response was not very close to the actual
responses (Figure 10). This is due to the fact that the regression line
calculated using the robust linear regression analysis does not pass
through the actual results.
Altogether, most of the patients have shown a relatively
good level of response to bevacizumab. However, no relationship
between this measure and patient survival length was found
(Table 3) (p,0.7, R=0.13). One reason may be that the anti-
angiogenesis drugs normalize the vascularity in the tumor area and
repair the blood brain barrier in this region without any specific
anti-tumor effects. This may be an explanation as to why
bevacizumab suppresses the Gd-enhanced area but has no
significant effect on the non-enhanced areas of the tumor [39,40].
Since the survival of the patients does not only depend on the Gd-
enhanced area of the tumor, no specific relationship between the
relative change in the size of this region and survival was found.
A practical limitation of this study is that the time between the
first two image acquisitions is not always the same, which may
have deteriorated the regression analysis results. Yet, this study
illustrates that it is possible to predict response of a brain tumor to
bevacizumab treatment before the treatment starts. Such a
prediction system may be instrumental for physician selection of
optimal treatment for their cancer patients.
In future studies, we intend to extract and evaluate other
imaging features from the Gd-enhanced and other sub-regions of
the tumor. We also intend to extend the proposed approach to
other tumor types and treatment options. Furthermore, we may
model shrinkage of the tumor cells based on the shape and texture
features of specific image regions.
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